Cytotoxic T cells derived from human T cell-derived iPS cells may avoid an NK cell missing-self response and may be used for allogeneic administration while maintaining a strong antitumor effect of antigen-specific CTLs. A method may produce a cytotoxic T cell derived from a human T cell-derived iPS cell expressing HLA class I of HLA-restricted class I of an antigen epitope of a CTL and HLA-E. Such a method may include: knocking out all HLA class I of the human T cell-derived iPS cell; introducing a gene of the HLA-restricted HLA class I of the antigen epitope of the CTL and a gene of the HLA-E into the T-iPS cell in which all HLA class I have been knocked out; and redifferentiating the genetically introduced T-iPS cell into a CD8 single-positive T cell.

The presently disclosed subject matter provides compositions, methods, and kits for transfecting adipose-derived mesenchymal stem cells (AMSCs) in freshly extracted adipose tissue using nanoparticles comprising biodegradable polymers self-assembled with nucleic acid molecules. The presently disclosed subject matter also provides methods for treating a neurological disease in a patient in need thereof, the method comprising administering the AMSCs transfected with the nucleic acid molecules to the patient, wherein the nucleic acid molecules encode one or more bioactive molecules functional in the treatment of a neurological disease, particularly wherein the neurological disease is a brain tumor.

Described herein are human genetically modified cells or precursors expressing fugetactic levels of a fugetactic agent, e.g. CXCL12, and methods of treating an autoimmune disease in a subject in need thereof. Also described herein are cells or precursors comprising a transgene or other genetic modification for expression of a nucleic acid sequence encoding a fugetactic agent, e.g. CXCL12.

Provided are a method for producing stem cell-derived extracellular vesicles by using a three-dimensional cell culture process, use of three-dimensional cell aggregates of stem cells in producing extracellular vesicles, a culture of three-dimensional cell aggregates of stem cells comprising a high concentration of extracellular vesicles, and a pharmaceutical composition comprising the culture.

The present disclosure includes genetically engineered, non-pathogenic Streptomyces bacterium with exogenous, non-native Thaxtomin A (ThxA) biosynthetic gene clusters conferring the genetically engineered, non-pathogenic Streptomyces bacterium with the ability to produce thaxtomin A. Also included are methods of providing thaxtomin producing capability in non-native Streptomyces bacterial strains, methods of producing thaxtomin compounds with the genetically engineered Streptomyces bacteria of the present disclosure, and methods of producing thaxtomin compounds and nitro-tryptophan analogs, and fluorinated thaxtomin compounds, analogs, and intermediates with the genetically engineered Streptomyces bacteria of the present disclosure.

Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.

The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.

Disclosed are compositions and methods related to recombinant cells expressing microRNA and an immunoglobulin gene.

The present invention discloses an antibody capable of binding to human interleukin 4 receptor alpha (hIL-4R alpha) and a preparation method and application thereof. The anti-hIL-4R alpha antibody can specifically bind to hIL-4R alpha, has good effects for inhibiting IL-4 and IL-13-induced cell line proliferation and the like, and can be applied to treatment of IL-4R alpha related diseases, such as immune-mediated inflammatory diseases.

A method for producing a product related to the specified technology includes adjusting the concentration of cells in a culture vessel to a value of from 3×10.sup.7 cells/ml to 3×10.sup.8 cells/ml; in a case in which the average diameter of single cells in the culture vessel is designated as A, adjusting the number proportion of cells having a single cell diameter of 1.4×A or greater in the culture vessel to 5% or less, and adjusting the number proportion of cells having a single cell diameter in the range of A±A/7 to 50% or more.